The relationship between uric acid levels and Huntington's disease progression

Authors

  • Peggy Auinger MS,

    Corresponding author
    1. Departments of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York
    • Department of Neurology, University of Rochester, 1351 Mt. Hope Ave., Rochester 14620, NY
    Search for more papers by this author
  • Karl Kieburtz MD,

    1. Departments of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York
    Search for more papers by this author
  • Michael P. Mcdermott PhD

    1. Departments of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York
    2. Departments of Biostatistics and Computational Biology, University of Rochester School of Medicine and Dentistry, Rochester, New York
    Search for more papers by this author

  • Potential confilct of interest: None.

Abstract

Uric acid (UA) may be associated with the progression of Parkinson's disease and related neurodegenerative conditions; however, its association with Huntington's disease (HD) progression has not been explored. A secondary analysis of 347 subjects from the CARE-HD clinical trial was performed to examine the relationship between baseline UA levels and the level of functional decline in HD. Outcomes included change in scores at 30 months for the Unified Huntington's Disease Rating Scale components. There was less worsening of total functional capacity over time with increasing baseline UA levels (adjusted mean worsening in scores: 3.17, 2.99, 2.95, 2.28, 2.21, from lowest to highest UA quintile, P = 0.03). These data suggest a possible association between higher UA levels and slower HD progression, particularly as measured by total functional capacity. If confirmed, UA could be an important predictor and potentially modifiable factor affecting the rate of HD progression. © 2009 Movement Disorder Society

Ancillary